ABVC Biopharma Files 8-K on Financials
Ticker: ABVC · Form: 8-K · Filed: Aug 14, 2025 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
ABVC Bio filed an 8-K on Aug 14, 2025, updating financials. No major news yet.
AI Summary
On August 14, 2025, ABVC Biopharma, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, but does not specify any new material events or significant financial figures within the provided text.
Why It Matters
This filing provides an update on ABVC Biopharma's financial status, which is crucial for investors to assess the company's performance and stability.
Risk Assessment
Risk Level: low — The filing is a routine update on financial condition and does not indicate any immediate negative developments.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- August 14, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 44370 Old Warm Springs Blvd. Fremont, CA 94538 (address) — Principal business address
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but the specific details of these statements are not provided in the excerpt.
What is the primary purpose of this 8-K filing for ABVC Biopharma?
The primary purpose is to report on the company's results of operations and financial condition.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 14, 2025.
What is ABVC Biopharma's state of incorporation?
ABVC Biopharma, Inc. is incorporated in Nevada.
Has ABVC Biopharma changed its name previously?
Yes, ABVC Biopharma, Inc. was formerly known as American BriVision (Holding) Corp, METU BRANDS, INC., and ECOLOGY COATINGS, INC. on various dates.
Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2025-08-14 07:02:46
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
Filing Documents
- ea0253086-8k_abvcbio.htm (8-K) — 25KB
- ea025308601ex99-1_abvcbio.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-076018.txt ( ) — 206KB
- abvc-20250814.xsd (EX-101.SCH) — 3KB
- abvc-20250814_lab.xml (EX-101.LAB) — 33KB
- abvc-20250814_pre.xml (EX-101.PRE) — 22KB
- ea0253086-8k_abvcbio_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On August 14, 2025, ABVC BioPharma, Inc. (the "Company") issued a press release announcing its financial results for second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information reported under this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company's securities in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File, formatted in Inline XBRL 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. August 14, 2025 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2